Solid matrix-antibody-antigen complexes incorporating equine herpesvirus 1 glycoproteins C and D elicit anti-viral immune responses in BALB/c (H-2K(d)) and C3H (H-2K(k)) mice.
Glycoproteins C and D (gC and gD) derived from equine herpesvirus 1 (EHV-1)-infected cells were incorporated into individual solid matrix-antibody-antigen (SMAA) complexes and administered to BALB/c (H-2K(d)) and C3H (H-2K(k)) mice. Antibodies against each of the glycoproteins were produced that neutralised virus infectivity and mediated the lysis of EHV-1-infected target cells in the presence of complement. Immunoglobulin (Ig)G2b was the predominant antibody isotype produced in BALB/c mice against gC, while equal amounts of IgG2a/2b were found in the serum of C3H mice (indicative of a T-helper(1) response). Glycoprotein D immunisation elicited predominantly an IgG1 response in BALB/c mice (indicative of a T-helper(2) response) and an IgG2a/2b response in C3H mice. EHV-1-specific local and systemic T-cell proliferative responses were detected in vitro following administration of SMAA complexes. Suppression of the local T-cell response was seen following virus challenge of mice immunised with SMAA gC. SMAA gD provided some protection against intranasal EHV-1 challenge. These data show that the SMAA system is an effective way of presenting subviral components to the immune system and further emphasises the importance of including glycoprotein D as a component of a subunit EHV-1 vaccine.
Alber
D G
DG
Wolfson Institute for Biomedical Research, University College London, WC1E 6AU, London, UK.
Killington
R A
RA
Stokes
A
A
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D000936:Antigen-Antibody Complex / Q000008:administration & dosage*; D000956:Antigens, Viral / Q000008:administration & dosage*; D004861:Herpesvirus 1, Equid / Q000276:immunology*; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D009500:Neutralization Tests; D013601:T-Lymphocytes / Q000276:immunology; D014759:Viral Envelope Proteins / Q000008:administration & dosage* / Q000276:immunology*
D000914:Antibodies, Viral; D000936:Antigen-Antibody Complex; D000956:Antigens, Viral; D014759:Viral Envelope Proteins; C080410:glycoprotein C, Equid herpesvirus 1; C488988:glycoprotein D, Equid herpesvirus 1